Wedbush Issues Positive Outlook for SWTX Earnings

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) – Wedbush increased their Q2 2025 earnings per share estimates for SpringWorks Therapeutics in a research note issued on Wednesday, February 12th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.68) for the quarter, up from their prior forecast of ($0.71). Wedbush has a “Outperform” rating and a $77.00 price target on the stock. The consensus estimate for SpringWorks Therapeutics’ current full-year earnings is ($3.03) per share. Wedbush also issued estimates for SpringWorks Therapeutics’ Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($2.43) EPS, FY2026 earnings at $0.23 EPS, FY2027 earnings at $3.55 EPS and FY2028 earnings at $8.09 EPS.

A number of other research firms also recently issued reports on SWTX. Evercore ISI increased their price objective on SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. HC Wainwright reiterated a “buy” rating and issued a $74.00 price objective on shares of SpringWorks Therapeutics in a report on Wednesday, February 12th. Finally, Guggenheim decreased their price objective on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $70.83.

SpringWorks Therapeutics Trading Down 2.0 %

SWTX opened at $56.30 on Monday. The stock has a fifty day simple moving average of $39.66 and a two-hundred day simple moving average of $37.02. The company has a market cap of $4.19 billion, a price-to-earnings ratio of -14.51 and a beta of 0.81. SpringWorks Therapeutics has a 12-month low of $28.21 and a 12-month high of $60.00.

Insider Activity

In other news, insider Daniel Pichl sold 29,750 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $54.36, for a total transaction of $1,617,210.00. Following the completion of the transaction, the insider now directly owns 50,762 shares in the company, valued at $2,759,422.32. This trade represents a 36.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Badreddin Edris sold 20,000 shares of SpringWorks Therapeutics stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total value of $839,400.00. Following the completion of the sale, the chief operating officer now owns 209,600 shares of the company’s stock, valued at $8,796,912. The trade was a 8.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 302,750 shares of company stock worth $16,139,410 over the last three months. 7.61% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On SpringWorks Therapeutics

Several large investors have recently bought and sold shares of SWTX. Huntington National Bank increased its holdings in SpringWorks Therapeutics by 38.2% in the 4th quarter. Huntington National Bank now owns 694 shares of the company’s stock worth $25,000 after buying an additional 192 shares in the last quarter. AlphaQuest LLC increased its holdings in SpringWorks Therapeutics by 70.2% in the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock worth $36,000 after buying an additional 414 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in SpringWorks Therapeutics during the 4th quarter valued at $45,000. State of Wyoming lifted its holdings in shares of SpringWorks Therapeutics by 39.5% during the 4th quarter. State of Wyoming now owns 1,530 shares of the company’s stock valued at $55,000 after buying an additional 433 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of SpringWorks Therapeutics by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock worth $87,000 after buying an additional 474 shares during the last quarter.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.